Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1045 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a price target of $1045.
August 16, 2023 | 3:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received a reiterated 'Buy' rating from Truist Securities, with a maintained price target of $1045.
The reiterated 'Buy' rating and maintained price target by Truist Securities indicates a positive outlook for Regeneron Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100